Stergiou Angelos M. 4
4 · SELLAS Life Sciences Group, Inc. · Filed Jan 25, 2024
Insider Transaction Report
Form 4
Stergiou Angelos M.
DirectorPresident and CEO
Transactions
- Award
Common Stock
2024-01-22+159,000→ 376,421 total - Award
Stock Option (Right to Buy)
2024-01-22+238,500→ 238,500 totalExercise: $0.52Exp: 2034-01-22→ Common Stock (238,500 underlying)
Footnotes (2)
- [F1]The Reporting Person received an award of 159,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
- [F2]One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.